Dongrui Ray Lu
Overview
Explore the profile of Dongrui Ray Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DeMichele A, Robert N, Chen C, Kim S, Zhang Z, Lu D, et al.
Target Oncol
. 2023 Jul;
18(4):543-558.
PMID: 37428347
Background: Limited real-world data exist regarding the efficacy of palbociclib in combination with endocrine therapy in pre/perimenopausal women with metastatic breast cancer. Objective: We aimed to compare real-world tumor responses...
2.
Mayer E, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein H, Zdenkowski N, et al.
J Clin Oncol
. 2022 Jan;
40(5):449-458.
PMID: 34995105
Purpose: The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human...
3.
Loi S, Karapetis C, McCarthy N, Oakman C, Redfern A, White M, et al.
Asia Pac J Clin Oncol
. 2021 Dec;
18(6):560-569.
PMID: 34908235
Aim: Palbociclib was approved in the United States in 2015 to treat estrogen receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). This study evaluated outcomes and safety...
4.
Gelmon K, Walshe J, Mahtani R, Joy A, Karuturi M, Neven P, et al.
Breast
. 2021 Aug;
59:321-326.
PMID: 34388698
Objective: In the PALOMA-2 trial, palbociclib in combination with letrozole prolonged progression-free survival (PFS) and exhibited an acceptable safety profile in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative...
5.
Mayer E, Dueck A, Martin M, Rubovszky G, Burstein H, Bellet-Ezquerra M, et al.
Lancet Oncol
. 2021 Jan;
22(2):212-222.
PMID: 33460574
Background: Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial aimed to investigate whether the addition of 2 years of palbociclib to...
6.
Rugo H, Finn R, Gelmon K, Joy A, Harbeck N, Castrellon A, et al.
Clin Breast Cancer
. 2019 Dec;
20(2):e173-e180.
PMID: 31836434
Background: In PALOMA-2, palbociclib + letrozole significantly prolonged progression-free survival (PFS) versus placebo + letrozole in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER/HER2) advanced breast cancer (ABC)....
7.
Hutson T, Escudier B, Esteban E, Bjarnason G, Lim H, Pittman K, et al.
J Clin Oncol
. 2013 Dec;
32(8):760-7.
PMID: 24297950
Purpose: This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target of rapamycin inhibitor) and sorafenib (vascular endothelial growth factor receptor [VEGFR]...
8.
Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C, et al.
N Engl J Med
. 2011 Feb;
364(6):501-13.
PMID: 21306237
Background: The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. Methods: We conducted a multinational, randomized, double-blind,...
9.
Bang Y, Kang Y, Kang W, Boku N, Chung H, Chen J, et al.
Invest New Drugs
. 2010 May;
29(6):1449-58.
PMID: 20461441
Purpose: This phase II, open-label, multicenter study assessed the oral, multitargeted, tyrosine kinase inhibitor sunitinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had received prior chemotherapy. Experimental...